duit Pharmaceuticals (CDT)

Search documents
duit Pharmaceuticals (CDT) - 2022 Q4 - Annual Report
2023-03-27 16:00
Title of each class Trading Symbol Name of each exchange on which registered FORM 10-K For the transition period from to Registrant's telephone number, including area code: 760-471-8536 None Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 1 ...
duit Pharmaceuticals (CDT) - 2022 Q3 - Quarterly Report
2022-11-06 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-41245 MURPHY CANYON ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction ...
duit Pharmaceuticals (CDT) - 2022 Q2 - Quarterly Report
2022-08-10 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-41245 MURPHY CANYON ACQUISITION CORP. | --- | --- | |---------------------------------------------------------------------------------- ...
duit Pharmaceuticals (CDT) - 2022 Q1 - Quarterly Report
2022-05-17 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-41245 MURPHY CANYON ACQUISITION CORP. | --- | --- | |--------------------------------------------------------------------------------- ...
duit Pharmaceuticals (CDT) - 2021 Q4 - Annual Report
2022-03-28 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 | --- | |-----------------------------------------------| | | | Units, each consisting of one share | | Class A Common Stock and one | | Redeemable Warrant | MURFU The Nasdaq Stock Market LLC | --- | --- | --- | |-----------------------------------------------------|-------|-------------------------------------| | | | | | Class A Common Stock, par value $0.0001 | MURF | The Nasdaq Stock Market LLC | | per share | | | | --- | |------------ ...